A prospective, single-center, single-arm, open label, feasibility study to evaluate safety and efficacy of MWA for unresectable lung cancer (SCIRO-2002) - SCIRO-2002

Tomita Koji0 个研究点目标入组 10 人开始时间: 2020年12月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Age of the patient 20 years old or older
•2) Lung tumor is clinically diagnosed as NSCLC (include local tumor progression) or metastatic cancer
•3) Refractory or unsuitable for surgical resection
•4) Size of the target lesion smaller than 3.0 cm
•5) Number of target lesion smaller than 3 in one lung and 6 in bilateral lung
•6) On spirometry test, FEV1 is greater than 1.0 L and %VC is greater than 80%
•7) No uncontrollable metastasis except on the lung
•8) All of the following conditions are met
•a) White blood-cell count >= 3000 /mm3
•b) platelet count >= 50,000 /mm3
•c) Hemogrobin >= 7.5 g/dl
•d) Prothrombin time-international normalized ratio <= 1.5

•1)Absence of the safe needle insertion pathway
•2)Presence of critical organ or vessel structures contact with target lesion
•3)Active infectious desease except viral hapatitis
•4)Active multiple cancers exept carcinoma in situ, intramucosal cancer, curative treated cancer, controlled breast cancer or prostate cancer
•5)Interstitial pneumonia is observed on chest X-ray or CT imaging
•6)Patients with cardiovascular implantable electronic devices
•7)Patients receiving antiplatelet, thrombolytic, or anticoagulant drugs who are unable to stop the drug temporarily or replace it with heparin
•8)Pregnant status
•9)Inappropriateness of the candidate for the study judged by the investigators because of other reasons

发起方

Tomita Koji